Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia
Authors: Freeman Tracelyn , Habib Alma , Huang Ying , Kumar Pooja , Waller Allyson , Fleming Megan , McMillan Kelsey , Hartzler Natalia , Behbehani Gregory K , Blachly James S. , Blaser Bradley Wayne , Borate Uma , Eisfeld Ann-Kathrin , Grieselhuber Nicole R. , Larkin Karilyn T. , Lee Shinae , Long Meixiao , Mims Alice , Srisuwananukorn Andrew , Sahasrabudhe Kieran D , Koenig Kristin L 
Published: December 2024

Introduction: Venetoclax (VEN) in combination with a hypomethylating agent (HMA) or low-dose cytarabine (LDAC), provides patients with acute myeloid leukemia (AML) a less intensive treatment option that has shown to be efficacious. However, this regimen creates potential challenges in management of toxicities and drug interactions, particularly in the presence of azole antifungals. Posaconazole (POSA) is a preferred prophylactic agent but introduces complexity due to its strong inhibition of the CYP3A4 enzyme and p-glycoprotein transporter affecting VEN metabolism leading to increased blood concentrations. As such, the optimal approach for dosing VEN with concurrent POSA is debatable and remains unknown. In 2021, our institution adopted the adjustment of VEN 100mg daily with POSA, mirroring other strong CYP3A4 inhibitors, but this is an increase from the recommended target dose of 70mg. Herein, we investigated the safety of VEN 100mg daily in comparison to VEN 70mg daily when administered concomitantly with POSA and aimed to provide a real-world clinical evaluation of these two proposed dosing strategies.

Methods: Adult patients with newly diagnosed (ND) or relapsed/refractory (R/R) AML treated with VEN 100mg or 70mg and HMA/LDAC plus concurrent POSA at The Ohio State University Comprehensive Cancer Center between November 2018 and February 2024 were included in this single-center retrospective cohort study. Eligible patients received a minimum of seven days of chemotherapy and at least one dose of POSA. Primary safety composite endpoints were incidence/duration of cytopenias and incidence of tumor lysis syndrome (TLS) during the first cycle. Secondary endpoints included combined complete remission (CR), CR with incomplete count recovery (CRi), and CR with partial hematologic recovery (CRh) within the first two cycles. The comparison between VEN 100mg and 70mg was conducted using chi-squared test or Fisher's exact test. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method.

Results: A total of 145 patients were included; 113 patients received VEN 100mg and 32 patients received 70mg. Baseline demographics were well-balanced between groups. Median age was 69.5 years, 56% were male, 60% had a performance status (Eastern Cooperative Oncology Group) of 1 at treatment start, and median follow-up was 13.2 months. Disease type was depicted by primary AML in 63.5%, ND in 69.0%, and complex karyotype in 28.5% of the total cohort. Disease risk, per European LeukemiaNet-2022, was poor in 64.9% and 68.8% and intermediate in 26.1% and 6.3% (p=0.0081) of patients treated with VEN 100mg and 70mg, respectively. Most patients within the total cohort received azacitidine/VEN (71%). Median duration in days of POSA was similar between 100mg and 70mg groups (74 vs 64, p=0.53); however, POSA was discontinued more often in lower dosed VEN (70mg 31.2% vs 100mg 15.0%, p=0.04), mostly due to abnormal liver function tests. Comparing VEN 100mg vs 70mg in cycle 1, no statistically significant differences were seen in grade 3 neutropenia (89.4% vs 84.4%, p=0.53), grade 4 neutropenia (88.5% vs 87.5%, p=1.0), median duration in days of grade 4 neutropenia (23 vs 28, p=0.35), grade 3/4 anemia (88.5% vs 84.4%, p=0.55), grade 3/4 thrombocytopenia (81.4% vs 87.5%, p=0.42), TLS (2.7% vs 6.3%, p=0.30), or hospitalizations for infection (9.4% vs 33.3%, p=0.09). Chemotherapy dose reductions during cycle 1 were significantly higher in patients dosed with less VEN (70mg 37.5% vs 100mg 14.2%, p=0.0031). Of the total cohort, 69 patients experienced at least one febrile neutropenia episode during cycle 1, with similar incidence seen between VEN 100mg and 70mg (47.8% vs 46.9%, p=0.93). Among evaluable patients who received VEN 100mg vs 70mg, combined CR/CRi/CRh by the start of cycle 3 was achieved in 50.0% vs 40.0% (p=0.42), with a median duration of response in months of 10.3 vs 11.7 (p=0.76), respectively. There were no significant differences in survival outcomes, in months, including median OS (7.0 vs 6.2, p=0.48) and PFS (5.7 vs 4.2, p=0.53).

Conclusions: In adult patients with either ND or R/R AML, an initial target dose of VEN 100mg may be a safe alternative to 70mg with POSA. Though dose reductions occurred more frequently with VEN 70mg, response rates between groups were similar. Larger prospective studies measuring venetoclax dose optimization are warranted for further evaluation.